Loading...
XTAI1707
Market cap681mUSD
Dec 25, Last price  
150.00TWD
1D
-0.99%
1Q
4.53%
Jan 2017
-19.79%
Name

Grape King Bio Ltd

Chart & Performance

D1W1MN
XTAI:1707 chart
P/E
15.30
P/S
2.09
EPS
9.81
Div Yield, %
4.60%
Shrs. gr., 5y
1.78%
Rev. gr., 5y
2.98%
Revenues
10.64b
+2.35%
1,489,681,0001,702,107,0002,112,457,0002,821,859,0003,282,274,0003,771,021,0004,611,719,0005,652,413,0006,282,859,0007,247,855,0009,185,021,0009,388,128,0009,183,321,0009,239,070,0009,168,195,0009,798,246,00010,391,231,00010,635,464,000
Net income
1.45b
-33.04%
150,422,000180,871,000164,522,000379,341,000427,700,000473,062,000618,902,000835,762,000942,483,0001,051,652,0001,296,769,0001,351,941,0001,295,394,0001,938,566,0001,895,095,0001,947,989,0002,169,687,0001,452,728,000
CFO
2.52b
-15.75%
468,842,000253,111,000434,852,000720,611,000683,894,000848,526,0001,121,257,0001,575,779,0001,701,422,0001,306,930,0002,803,128,0002,495,656,0002,417,429,0002,171,439,0002,719,190,0002,542,204,0002,990,437,0002,519,402,000
Dividend
Jan 21, 20252.7 TWD/sh
Earnings
Feb 24, 2025

Profile

Grape King Bio Ltd produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy foods in Taiwan, China, and internationally. It operates through Multi-Level Marketing, Distributors, and Original Design Manufacturer/Original Equipment Manufacturer (ODM/OEM) segments. The company offers mushroom mycelium products, such as ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor; probiotics, including enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium; and enzymes. It also provides OEM, ODM, formulation design, research and development, and raw material supply services. The company was founded in 1969 and is headquartered in Taoyuan City, Taiwan.
URL
https://www.grapeking.com.tw/
IPO date
Dec 20, 1982
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
10,635,464
2.35%
10,391,231
6.05%
9,798,246
6.87%
Cost of revenue
8,136,323
7,838,398
7,486,092
Unusual Expense (Income)
NOPBT
2,499,141
2,552,833
2,312,154
NOPBT Margin
23.50%
24.57%
23.60%
Operating Taxes
519,109
518,191
466,917
Tax Rate
20.77%
20.30%
20.19%
NOPAT
1,980,032
2,034,642
1,845,237
Net income
1,452,728
-33.04%
2,169,687
11.38%
1,947,989
2.79%
Dividends
(1,022,148)
(903,638)
(948,079)
Dividend yield
4.39%
3.61%
3.99%
Proceeds from repurchase of equity
1,970,552
BB yield
-8.30%
Debt
Debt current
56,560
46,943
55,301
Long-term debt
329,280
268,561
393,850
Deferred revenue
7,362
Other long-term liabilities
20,515
19,043
44,346
Net debt
(6,081,025)
(4,440,863)
(3,236,109)
Cash flow
Cash from operating activities
2,519,402
2,990,437
2,542,204
CAPEX
(587,179)
(502,469)
(278,401)
Cash from investing activities
(654,732)
(330,309)
(462,344)
Cash from financing activities
(1,708,931)
(1,628,551)
(1,369,013)
FCF
1,769,960
1,905,715
1,937,622
Balance
Cash
4,969,911
4,789,901
3,897,434
Long term investments
1,496,954
(33,534)
(212,174)
Excess cash
5,935,092
4,236,805
3,195,348
Stockholders' equity
8,833,146
8,285,152
7,576,303
Invested Capital
5,908,278
6,054,972
6,631,810
ROIC
33.10%
32.07%
27.26%
ROCE
20.96%
24.64%
23.36%
EV
Common stock shares outstanding
149,122
149,062
148,400
Price
156.00
-7.14%
168.00
5.00%
160.00
-9.86%
Market cap
23,263,032
-7.11%
25,042,416
5.47%
23,744,000
-2.28%
EV
18,833,643
22,172,854
21,949,012
EBITDA
2,958,904
3,002,471
2,739,607
EV/EBITDA
6.37
7.38
8.01
Interest
2,538
2,367
4,011
Interest/NOPBT
0.10%
0.09%
0.17%